Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Traditional NSAIDs Do Not Raise Cardiovascular Risk – JAMA Review

Sep 18 2006

• By Rebekah Moan

Related Content

Naproxen Label Shows Limitations Of Class Effect Thinking – Harvard’s Avorn

Sep 12 2005

Naproxen Could Serve As NSAID Safety Trial Standard, Advisory Panel Says

Feb 21 2005

High-Dose Ibuprofen, COX-2s Show Similar Vascular Event Risk – Study

Jun 05 2006

Merck Vioxx Detailing Should Have Addressed VIGOR Risks – FDA’s Jenkins

May 09 2005

Naproxen Heart Concerns Surface In Halted NIH Alzheimer’s Trial

Jan 03 2005

FDA Determines A “Class Effect” Is In Play For All NSAIDs

Apr 11 2005

Lack Of FDA Trial Authority, DTC Marketing Caused COX-2 Crisis – Topol

Jan 10 2005

Additional Topics

OTC Drugs Consumer

More from Archive

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window